Abstract:Abstract Immunotherapies that modulate T cell function have been firmly established in cancer immunotherapy, whereas the potential for B cells in the antitumor immune response is not as well understood. B cell-activating factor (BAFF) is a cytokine belonging to the TNF ligand family that activates B cells and is linked to autoimmunity. Our preliminary research has identified BAFF as a target for enhancing antitumor immunity through enhancing presentation of tumor neoantigens and inducing tertiary lymphoid structures which can orchestrate tumor-specific T cell immune responses and correlate with improved clinical response. Since broad activation of B cell response could be detrimental and possibly induce autoimmune side effects, identification of specific B cell receptors that coordinate anti-tumor immunity is prudent. BAFF has three known receptors (BAFF-R, TACI and BCMA), and the effects of these specific BAFF ligand-receptor interactions on antitumor immunity are not known. Here we first generated BAFF-overexpressing cell lines using genomic editing [KPC-BAFF (pancreas), B16F10-BAFF (melanoma), and PancO2-BAFF (pancreas)] and examined their tumor growth in syngeneic immunocompetent host. Secondly, we investigated the effects of BAFF-overexpression on tumor response when individual receptors are knocked out using BAFF-R-KO, TACI-KO and BCMA-KO mice. Our results show significantly hindered tumor growth when the BAFF expressing stable cell lines are introduced to immunocompetent host, compared to parental cell lines. Tumor response experiments in receptor knockout mice is currently in progress. Successful identification of the BAFF receptor candidate that drives anti-tumor response is an exciting prospect for clinical translation. Development of agonists for the specific receptor may allow selective modulation of this particular B cell function in context of cancer therapy without perturbation of broad systemic humoral immunity. Citation Format: Khaled Aziz, Kabeer Munjal, Kathryn Howe, Mark Yarchoan. B-cell activating factor (BAFF) enhances antitumor immunity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3978.

Current status of BAFF targeting immunotherapy in B-cell neoplasm

[Advances of using antibody against B cell activating factor for treatment of autoimmune diseases].

Abstract 3978: B-cell activating factor (BAFF) enhances antitumor immunity

Expression of BAFF-R and TACI in reactive lymphoid tissues and B-cell lymphomas

B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases

The Function of BAFF on T Helper Cells in Autoimmunity.

The Role BAFF and BAFF Receptors in Macrophage Induced Drug Resistance of Multiple Myeloma

BAFF-targeting Therapy, a Promising Strategy for Treating Autoimmune Diseases

B Cell-Activating Factor and Its Targeted Therapy in Autoimmune Diseases.

Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions

BAFF promotes follicular helper T cell development and germinal center formation through BR3 signal

The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity

BAFF Binding to T Cell-Expressed BAFF-R Promotes Follicular Helper T Cell Proliferation and GC B Cell Responses

An unappreciated cell survival-independent role for BAFF initiating chronic lymphocytic leukemia

A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers

Contributions of each of the BAFF receptors to the lymphocyte profiles in C57BL/6 mice

BAFF and Selection of Autoreactive B Cells

Expressions of BAFF/BAFF Receptors and Their Correlation with Disease Activity in Chinese SLE Patients

BAFF overexpression in triple-negative breast cancer promotes tumor growth by inducing IL-10-secreting regulatory B cells that suppress anti-tumor T cell responses

B Lymphocyte Stimulator: a New Target for Treating B Cell Malignancies

Effect of BAFF blockade on the B cell receptor repertoire and transcriptome in a mouse model of systemic lupus erythematosus